Literature DB >> 23397290

Treatment of epileptic encephalopathies.

Amy McTague1, J Helen Cross.   

Abstract

Epileptic encephalopathy is defined as a condition where the epileptic activity itself may contribute to the severe neurological and cognitive impairment seen, over and above that which would be expected from the underlying pathology alone. The epilepsy syndromes at high risk of this are a disparate group of conditions characterized by epileptic seizures that are difficult to treat and developmental delay. In this review, we discuss the ongoing debate regarding the significance of inter-ictal discharges and the impact of the seizures themselves on the cognitive delay or regression that is a common feature of these syndromes. The syndromes also differ in many ways and we provide a summary of the key features of the early-onset epileptic encephalopathies including Ohtahara and West syndromes in addition to later childhood-onset syndromes such as Lennox Gastaut and Doose syndromes. An understanding of the various severe epilepsy syndromes is vital to understanding the rationale for treatment. For example, the resolution of hypsarrhythmia in West syndrome is associated with an improvement in cognitive outcome and drives treatment choice, but the same cannot be applied to frequent inter-ictal discharges in Lennox Gastaut syndrome. We discuss the evidence base for treatment where it is available and describe current practice where it is not. For example, in West syndrome there is some evidence for preference of hormonal treatments over vigabatrin, although the choice and duration of hormonal treatment remains unclear. We describe the use of conventional and newer anti-epileptic medications in the various syndromes and discuss which medications should be avoided. Older possibly forgotten treatments such as sulthiame and potassium bromide also have a role in the severe epilepsies of childhood. We discuss hormonal treatment with particular focus on the treatment of West syndrome, continuous spike wave in slow wave sleep (CSWS)/electrical status epilepticus in slow wave sleep (ESES) and Landau Kleffner syndrome. The role of the ketogenic diet has in recent years come to the fore of the management of these severe epilepsies and we describe successful use in myoclonic astatic epilepsy, Lennox Gastaut syndrome and Dravet syndrome. It is important that resective epilepsy surgery is not ignored in the management of these children, particularly those with hemi-pathology who may present with ESES and respond well to hemispheric disconnection. Adjunctive and symptomatic surgical treatments such as vagal nerve stimulation and corpus callosotomy may improve seizure burden. Finally, it is vital that the identification and treatment of developmental, behavioural and psychiatric co-morbidities are not neglected and that a rational, holistic approach is taken to the management of epileptic encephalopathies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23397290     DOI: 10.1007/s40263-013-0041-6

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  56 in total

1.  Impaired mitochondrial glutamate transport in autosomal recessive neonatal myoclonic epilepsy.

Authors:  Florence Molinari; Annick Raas-Rothschild; Marlene Rio; Giuseppe Fiermonte; Ferechte Encha-Razavi; Luigi Palmieri; Ferdinando Palmieri; Ziva Ben-Neriah; Noman Kadhom; Michel Vekemans; Tania Attie-Bitach; Arnold Munnich; Pierre Rustin; Laurence Colleaux
Journal:  Am J Hum Genet       Date:  2004-12-08       Impact factor: 11.025

2.  Ketogenic diet in patients with myoclonic-astatic epilepsy.

Authors:  Roberto Horacio Caraballo; Ricardo Oscar Cersósimo; Diego Sakr; Araceli Cresta; Nidia Escobal; Natalio Fejerman
Journal:  Epileptic Disord       Date:  2006-06       Impact factor: 1.819

3.  The risk of lower mental outcome in infantile spasms increases after three weeks of hypsarrhythmia duration.

Authors:  Zvonka Rener Primec; Janez Stare; David Neubauer
Journal:  Epilepsia       Date:  2006-12       Impact factor: 5.864

Review 4.  Corticosteroids including ACTH for childhood epilepsy other than epileptic spasms.

Authors:  N A Gayatri; C D Ferrie; H Cross
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

5.  Efficacy of felbamate in the treatment of intractable pediatric epilepsy.

Authors:  Mary L Zupanc; Rhonda Roell Werner; Michael S Schwabe; Sunila E O'Connor; Charles J Marcuccilli; Kurt E Hecox; Maria S Chico; Kathy A Eggener
Journal:  Pediatr Neurol       Date:  2010-06       Impact factor: 3.372

6.  The fat is in the fire: ketogenic diet for refractory status epilepticus.

Authors:  Eric Kossoff
Journal:  Epilepsy Curr       Date:  2011-05       Impact factor: 7.500

7.  Long-term follow-up of febrile infection-related epilepsy syndrome.

Authors:  Katherine B Howell; Kamornwan Katanyuwong; Mark T Mackay; Catherine A Bailey; Ingrid E Scheffer; Jeremy L Freeman; Samuel F Berkovic; A Simon Harvey
Journal:  Epilepsia       Date:  2011-12-22       Impact factor: 5.864

8.  Myoclonic astatic epilepsy: an age-dependent epileptic syndrome with favorable seizure outcome but variable cognitive evolution.

Authors:  Marina Trivisano; Nicola Specchio; Simona Cappelletti; Vincenzo Di Ciommo; Dianela Claps; Luigi M Specchio; Federico Vigevano; Lucia Fusco
Journal:  Epilepsy Res       Date:  2011-08-27       Impact factor: 3.045

9.  Developmental outcomes in children receiving resection surgery for medically intractable infantile spasms.

Authors:  R F Asarnow; C LoPresti; D Guthrie; T Elliott; V Cynn; W D Shields; D A Shewmon; R Sankar; W J Peacock
Journal:  Dev Med Child Neurol       Date:  1997-07       Impact factor: 5.449

10.  Expansion of the first PolyA tract of ARX causes infantile spasms and status dystonicus.

Authors:  R Guerrini; F Moro; M Kato; A J Barkovich; T Shiihara; M A McShane; J Hurst; M Loi; J Tohyama; V Norci; K Hayasaka; U J Kang; S Das; W B Dobyns
Journal:  Neurology       Date:  2007-07-31       Impact factor: 9.910

View more
  15 in total

Review 1.  Epileptic encephalopathies: new genes and new pathways.

Authors:  Sahar Esmaeeli Nieh; Elliott H Sherr
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

2.  Dravet in the dish: mechanisms of hyperexcitability.

Authors:  Detlev Boison
Journal:  Epilepsy Curr       Date:  2014-09       Impact factor: 7.500

Review 3.  Childhood Electroclinical Syndromes: a diagnostic and therapeutic algorithm.

Authors:  Pratibha Singhi
Journal:  Indian J Pediatr       Date:  2014-08-07       Impact factor: 1.967

4.  STXBP1 encephalopathies: Clinical spectrum, disease mechanisms, and therapeutic strategies.

Authors:  Debra Abramov; Noah Guy Lewis Guiberson; Jacqueline Burré
Journal:  J Neurochem       Date:  2020-08-04       Impact factor: 5.372

5.  Adrenocorticotropic hormone protects learning and memory function in epileptic Kcna1-null mice.

Authors:  Morris H Scantlebury; Kyoung-Chul Chun; Shun-Chieh Ma; Jong M Rho; Do Young Kim
Journal:  Neurosci Lett       Date:  2017-02-27       Impact factor: 3.046

Review 6.  Current Treatment Options for Early-Onset Pediatric Epileptic Encephalopathies.

Authors:  Rolla Shbarou
Journal:  Curr Treat Options Neurol       Date:  2016-10       Impact factor: 3.598

7.  Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.

Authors:  Brenda E Porter; Catherine Jacobson
Journal:  Epilepsy Behav       Date:  2013-12       Impact factor: 2.937

Review 8.  The Clinical Spectrum of Benign Epilepsy with Centro-Temporal Spikes: a Challenge in Categorization and Predictability.

Authors:  Yun Jeong Lee; Su Kyeong Hwang; Soonhak Kwon
Journal:  J Epilepsy Res       Date:  2017-06-30

Review 9.  The Current Status of the Ketogenic Diet in Psychiatry.

Authors:  Emmanuelle C S Bostock; Kenneth C Kirkby; Bruce V M Taylor
Journal:  Front Psychiatry       Date:  2017-03-20       Impact factor: 4.157

10.  Genetic basis of pediatric epilepsy syndromes.

Authors:  Dongli Zhang; Xiaoming Liu; Xingqiang Deng
Journal:  Exp Ther Med       Date:  2017-03-27       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.